Clinical Utility of Simultaneous Measurement of Serum High-sensitivity Des-gamma-carboxy Prothrombin and Lens Culinaris Agglutinin A-reactive Alpha-fetoprotein in Patients with Small Hepatocellular Carcinoma
Overview
Affiliations
Objective: To evaluate the diagnostic efficacy of simultaneous measurements of high-sensitivity des-gamma-carboxy prothrombin (H-DCP) and Lens culinaris agglutinin A-reactive alpha-fetoprotein (AFP-L3) in small hepatocellular carcinoma (HCC).
Methods: Sixty-one patients with small HCCs < or = 2 cm in diameter and 134 controls (chronic hepatitis: 59 cases; cirrhosis: 75 cases) were examined. H-DCP was measured by electrochemiluminescence immunoassay (cut-off 40 mAU/ml (milli-arbitrary units/ml) and AFP-L3% (percentage of AFP-L3/total AFP) by lectin-affinity electrophoresis coupled with the antibody-affinity blotting method (cut-off 10%). Fifty-six patients were histologically diagnosed and the remaining five patients were diagnosed clinically.
Results: Of 61 patients, 27 (44.3%) were positive for H-DCP and 14 (23.0%) were positive for AFP-L3. There was no correlation between H-DCP and AFP-L3%. Nineteen patients (31.1%) had positive H-DCP alone. Six patients (9.8%) had positive AFP-L3 alone, and in eight patients (13.1%) both markers were positive. In combination assay, 33 of 61 patients (54.1%) were positive for either marker; specificity and accuracy were 97.8% and 84.1%, respectively. There was a tendency for the AFP-L3% to be elevated in patients with moderately or poorly differentiated HCC (P= 0.0564) and multiple HCC nodules (P= 0.0316), while the H-DCP showed no elevation related to the tumour type.
Conclusion: The detection rate of small HCC was improved by combination assay with H-DCP and AFP-L3%. Our results indicate that the markers are complementary and useful for the diagnosis and evaluation of small HCC when measured simultaneously.
Shahini E, Pasculli G, Solimando A, Tiribelli C, Cozzolongo R, Giannelli G Int J Mol Sci. 2023; 24(5).
PMID: 36901717 PMC: 10001986. DOI: 10.3390/ijms24054286.
Nagahara T, Sugihara T, Kihara T, Ikeda S, Hoshino Y, Matsuki Y Cancers (Basel). 2023; 15(2).
PMID: 36672339 PMC: 9856355. DOI: 10.3390/cancers15020390.
Parikh N, Tayob N, Singal A J Hepatol. 2022; 78(1):207-216.
PMID: 36089157 PMC: 10229257. DOI: 10.1016/j.jhep.2022.08.036.
Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Stimac D Cochrane Database Syst Rev. 2021; 4:CD013346.
PMID: 33855699 PMC: 8078581. DOI: 10.1002/14651858.CD013346.pub2.
Novel biomarkers for the management of chronic hepatitis B.
Inoue T, Tanaka Y Clin Mol Hepatol. 2020; 26(3):261-279.
PMID: 32536045 PMC: 7364351. DOI: 10.3350/cmh.2020.0032.